[Clinical and in-vitro studies of the therapeutical range of acetylsalicylic-acid to prevent deep vein thrombosis (author's transl)].
In three consecutive studies, acetylsalicyliclysine using the dosages 0.9 g/48 h, 1.8 g/24 h and 3.6 g/24 h, was examined in order to see its effect in preventing deep vein thrombosis (DVT) after elective hip joint surgery. DVT was diagnosed by the 125-i-fibrinogen-test.  No reduction of postoperative DVT was found under any of the administered AS-lysine dosages. The collagen-induced platelet aggregation was significantly decreased in all three groups. However, under the low AS-lysine dosages, aggregation was less inhibited with the incidence of DVT than without DVT. In the group with the 3.6 g-dosage, aggregation was maximally inhibited, without any significant difference related to the occurrence of DVT. The results reveal no therapeutic range of AS-lysine to prevent postoperative venous thrombosis.
D000368:Aged; D001241:Aspirin / Q000008:administration & dosage*; D006621:Hip Joint / Q000601:surgery; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D011183:Postoperative Complications / Q000517:prevention & control; D013924:Thrombophlebitis / Q000517:prevention & control*
D001241:Aspirin
Klinische und in vitro-Untersuchungen zur therapeutischen Breite von Acetylsalicylsäure zur Thromboseprophylaxe.